U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C22H24BrFN4O2
Molecular Weight 475.354
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VANDETANIB

SMILES

COC1=CC2=C(NC3=CC=C(Br)C=C3F)N=CN=C2C=C1OCC4CCN(C)CC4

InChI

InChIKey=UHTHHESEBZOYNR-UHFFFAOYSA-N
InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/25982012

Vandetanib, 4-anilinoquinazoline, is an anti-cancer drug that with the potential for use in a broad range of tumour types. In 2011 vandetanib (trade name Caprelsa) was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. In vitro studies have shown that vandetanib inhibits the tyrosine kinase activity of the EGFR and VEGFR families, RET, BRK, TIE2, and members of the EPH receptor and Src kinase families. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment. Vandetanib was shown to inhibit epidermal growth factor (EGF)-stimulated receptor tyrosine kinase phosphorylation in tumor cells and endothelial cells and VEGF-stimulated tyrosine kinase phosphorylation in endothelial cells. Vandetanib administration reduced tumor cell-induced angiogenesis, tumor vessel permeability, and inhibited tumor growth and metastasis in mouse models of cancer.

CNS Activity

Originator

Approval Year

2011
587
Targets

Targets

Primary TargetPharmacologyConditionPotency
Epidermal growth factor receptor
49
Target ID: P00533|||Q9GZX1
Gene ID: 1956.0
Gene Symbol: EGFR
Target Organism: Homo sapiens (Human)
Inhibitor
8504
 0.5 µM [IC50]
Vascular endothelial growth factor receptor 2
112
Target ID: P35968
Gene ID: 3791.0
Gene Symbol: KDR
Target Organism: Homo sapiens (Human)
Inhibitor
8504
 0.04 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8583
CAPRELSA

Approved Use

Indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA.

Launch Date

2011
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2024 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000ClinPharmR.pdf
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VANDETANIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
130 ng/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000ClinPharmR.pdf
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VANDETANIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
38611 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000ClinPharmR.pdf
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VANDETANIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
22030 ng × h/mL
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000ClinPharmR.pdf
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VANDETANIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.6 day
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000ClinPharmR.pdf
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VANDETANIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
204 h
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000ClinPharmR.pdf
300 mg single, oral
dose: 300 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VANDETANIB plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
6%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000ClinPharmR.pdf
300 mg 1 times / day steady-state, oral
dose: 300 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VANDETANIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
1200 mg single, oral
Highest studied dose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/22206795/
healthy, mean age 34.4 years
Health Status: healthy
Age Group: mean age 34.4 years
Sex: M
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/22206795/
Other AEs: Rash, Blood pressure systolic increased...
Other AEs:
Rash
Blood pressure systolic increased
Blood pressure diastolic increased
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/22206795/
300 mg single, oral
Studied dose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
healthy, mean age 34.4 years
Health Status: healthy
Age Group: mean age 34.4 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
Disc. AE: Vomiting...
AEs leading to
discontinuation/dose reduction:
Vomiting (grade 2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
400 mg single, oral
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/22206795/
healthy, mean age 34.4 years
Health Status: healthy
Age Group: mean age 34.4 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/22206795/
Disc. AE: Eczema...
AEs leading to
discontinuation/dose reduction:
Eczema (grade 1)
Sources:
https://pubmed.ncbi.nlm.nih.gov/22206795/
800 mg single, oral
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/22206795/
healthy, mean age 34.4 years
Health Status: healthy
Age Group: mean age 34.4 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/22206795/
Disc. AE: Folliculitis...
AEs leading to
discontinuation/dose reduction:
Folliculitis (grade 2)
Sources:
https://pubmed.ncbi.nlm.nih.gov/22206795/
200 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
unhealthy, mean age 45.6 years
Health Status: unhealthy
Age Group: mean age 45.6 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
DLT: Hypophosphatemia, Diarrhea...
Dose limiting toxicities:
Hypophosphatemia (grade 3, 12.5%)
Diarrhea (grade 2, 12.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
unhealthy, mean age 50.6 years
Health Status: unhealthy
Age Group: mean age 50.6 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
DLT: Intestinal obstruction, Diarrhea...
Dose limiting toxicities:
Intestinal obstruction (grade 3, 12.5%)
Diarrhea (grade 3, 25%)
Colitis (grade 3, 12.5%)
Hypertension (grade 3, 12.5%)
Fatigue (grade 3, 12.5%)
Thrombocytopenia (grade 3, 12.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Disc. AE: Skin disorder, Asthenia...
Other AEs: Rash, Acneiform dermatitis...
AEs leading to
discontinuation/dose reduction:
Skin disorder (2.5%)
Asthenia (1.7%)
Fatigue (0.9%)
Pyrexia (0.9%)
Diarrhea (0.9%)
Creatinine increased (0.9%)
Electrocardiogram QTc interval prolonged (0.9%)
Hypertension (0.9%)
General physical health deterioration (0.4%)
Dysphagia (0.4%)
Nausea (0.4%)
Pancreatitis (0.4%)
Peritonitis (0.4%)
Small intestinal perforation (0.4%)
Vomiting (0.4%)
Systolic dysfunction (0.4%)
Chylothorax (0.4%)
Cough (0.4%)
Dysphonia (0.4%)
Dyspnea (0.4%)
Pneumonitis (0.4%)
Peripheral ischemia (0.4%)
Peripheral sensorimotor neuropathy (0.4%)
Vision blurred (0.4%)
Arthralgia (0.4%)
Germ cell cancer (0.4%)
Other AEs:
Rash (grade 3, 3.9%)
Acneiform dermatitis (grade 3, 0.9%)
Photosensitivity reaction (grade 3, 1.7%)
Generalized erythema (grade 3, 1.3%)
Skin exfoliation (grade 3, 0.4%)
Palmar-plantar erythrodysaesth. (grade 3, 0.4%)
Dermatitis bullous (grade 3, 0.4%)
Skin candida (grade 3, 0.4%)
Erysipelas (grade 3, 0.4%)
Pneumonitis (grade 3, 0.4%)
Dyspnea (grade 3, 1.7%)
Respiratory failure (grade 3, 0.8%)
Diarrhea (grade 3, 3%)
Nausea (grade 3, 1%)
Hypertension (grade 3, 6%)
Headache (grade 3, 1%)
Fatigue (grade 3, 6%)
Decreased appetite (grade 3, 4%)
Dermatitis acneiform (grade 3, <1%)
Vomiting (grade 3, 1%)
Asthenia (grade 3, 3%)
Abdominal pain (grade 3, 2%)
QT interval prolonged (grade 3, 8%)
Photosensitivity reaction (grade 3, 2%)
Hypocalcaemia (grade 3, 2%)
Pruritus (grade 3, 1%)
Weight decreased (grade 3, 1%)
Depression (grade 3, 2%)
ALT increased (grade 3, 2%)
Calcium decreased (grade 3, 6%)
Calcium increased (grade 3, 9%)
Glucose increased (grade 3, 2%)
Magnesium decreased (grade 3, <1%)
Potassium decreased (grade 3, <1%)
Potassium increased (grade 3, <1%)
Hemoglobin decreased (grade 3, <1%)
Neutrophil count decreased (grade 3, <1%)
WBC decreased (grade 3, <1%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
500 mg 1 times / day multiple, oral
Dose: 500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 500 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
unhealthy, mean age 51.6 years
Health Status: unhealthy
Age Group: mean age 51.6 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
DLT: Diarrhea, Folliculitis...
Disc. AE: Folliculitis...
Dose limiting toxicities:
Diarrhea (grade 2, 12.5%)
Folliculitis (grade 2, 12.5%)
ALT increased (grade 3, 12.5%)
Rash (grade 3, 12.5%)
AEs leading to
discontinuation/dose reduction:
Folliculitis (grade 3, 12.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
unhealthy, mean age 57.7 years
Health Status: unhealthy
Age Group: mean age 57.7 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
DLT: Rash...
Disc. AE: Congestive cardiac failure...
Dose limiting toxicities:
Rash (grade 2, 4%)
AEs leading to
discontinuation/dose reduction:
Congestive cardiac failure (grade 3, 4%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
unhealthy, median age 50 years
Health Status: unhealthy
Age Group: median age 50 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
Other AEs: Lymphopenia...
Other AEs:
Lymphopenia (grade 3, 33.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
200 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
unhealthy, median age 52.5 years
Health Status: unhealthy
Age Group: median age 52.5 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
DLT: Hypertension...
Other AEs: Fatigue...
Dose limiting toxicities:
Hypertension (grade 3, 33.3%)
Other AEs:
Fatigue (grade 3, 16.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
400 mg 1 times / day multiple, oral
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
unhealthy, median age 53 years
Health Status: unhealthy
Age Group: median age 53 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
DLT: Hypertension, Alanine aminotransferase increased...
Dose limiting toxicities:
Hypertension (grade 3, 33.3%)
Alanine aminotransferase increased (grade 3, 33.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
unhealthy, median age 55.5 years
Health Status: unhealthy
Age Group: median age 55.5 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
DLT: Hypertension, Diarrhea...
Dose limiting toxicities:
Hypertension (grade 3, 33.3%)
Diarrhea (grade 3, 33.3%)
Headache (grade 3, 33.3%)
Toxic skin eruption (grade 2, 33.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Disc. AE: Rash, Dyspnea...
Other AEs: Diarrhea, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Rash (1.3%)
Dyspnea (1%)
Pneumonia (1.1%)
Other AEs:
Diarrhea (50%)
Diarrhea (grade 3-4, 5%)
Rash (28%)
Rash (grade 3-4, 3%)
Nausea (23%)
Nausea (grade 3-4, 1%)
Anorexia (20%)
Anorexia (grade 3-4, 2%)
Fatigue (20%)
Fatigue (grade 3-4, 4%)
Dyspnea (15%)
Dyspnea (grade 3-4, 4%)
Cough (13%)
Cough (grade 3-4, 0.8%)
Dermatitis acneiform (12%)
Dermatitis acneiform (grade 3-4, 0.6%)
Vomiting (14%)
Vomiting (grade 3-4, 2%)
Constipation (9%)
Dry skin (10%)
Dry skin (grade 3-4, 0.3%)
Hypertension (16%)
Hypertension (grade 3-4, 4%)
Pruritus (6%)
Pruritus (grade 3-4, 0.5%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/21282542/
Other AEs: QT interval prolonged, Torsades de pointes...
Other AEs:
QT interval prolonged (5.1%)
Torsades de pointes (0.2%)
Sudden death (grade 5, 0.2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/21282542/
AEs

AEs

AESignificanceDosePopulation
Blood pressure diastolic increased
1200 mg single, oral
Highest studied dose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/22206795/
healthy, mean age 34.4 years
Health Status: healthy
Age Group: mean age 34.4 years
Sex: M
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/22206795/
Blood pressure systolic increased
1200 mg single, oral
Highest studied dose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/22206795/
healthy, mean age 34.4 years
Health Status: healthy
Age Group: mean age 34.4 years
Sex: M
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/22206795/
Rash
1200 mg single, oral
Highest studied dose
Dose: 1200 mg
Route: oral
Route: single
Dose: 1200 mg
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/22206795/
healthy, mean age 34.4 years
Health Status: healthy
Age Group: mean age 34.4 years
Sex: M
Sources:
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
https://pubmed.ncbi.nlm.nih.gov/22206795/
Vomiting grade 2
Disc. AE
300 mg single, oral
Studied dose
Dose: 300 mg
Route: oral
Route: single
Dose: 300 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
healthy, mean age 34.4 years
Health Status: healthy
Age Group: mean age 34.4 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
Eczema grade 1
Disc. AE
400 mg single, oral
Dose: 400 mg
Route: oral
Route: single
Dose: 400 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/22206795/
healthy, mean age 34.4 years
Health Status: healthy
Age Group: mean age 34.4 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/22206795/
Folliculitis grade 2
Disc. AE
800 mg single, oral
Dose: 800 mg
Route: oral
Route: single
Dose: 800 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/22206795/
healthy, mean age 34.4 years
Health Status: healthy
Age Group: mean age 34.4 years
Sex: M
Sources:
https://pubmed.ncbi.nlm.nih.gov/22206795/
Diarrhea grade 2, 12.5%
DLT
200 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
unhealthy, mean age 45.6 years
Health Status: unhealthy
Age Group: mean age 45.6 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
Hypophosphatemia grade 3, 12.5%
DLT
200 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
unhealthy, mean age 45.6 years
Health Status: unhealthy
Age Group: mean age 45.6 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
Colitis grade 3, 12.5%
DLT
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
unhealthy, mean age 50.6 years
Health Status: unhealthy
Age Group: mean age 50.6 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
Fatigue grade 3, 12.5%
DLT
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
unhealthy, mean age 50.6 years
Health Status: unhealthy
Age Group: mean age 50.6 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
Hypertension grade 3, 12.5%
DLT
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
unhealthy, mean age 50.6 years
Health Status: unhealthy
Age Group: mean age 50.6 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
Intestinal obstruction grade 3, 12.5%
DLT
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
unhealthy, mean age 50.6 years
Health Status: unhealthy
Age Group: mean age 50.6 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
Thrombocytopenia grade 3, 12.5%
DLT
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
unhealthy, mean age 50.6 years
Health Status: unhealthy
Age Group: mean age 50.6 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
Diarrhea grade 3, 25%
DLT
600 mg 1 times / day multiple, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
unhealthy, mean age 50.6 years
Health Status: unhealthy
Age Group: mean age 50.6 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
Arthralgia 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Chylothorax 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Cough 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Dysphagia 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Dysphonia 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Dyspnea 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
General physical health deterioration 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Germ cell cancer 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Nausea 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Pancreatitis 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Peripheral ischemia 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Peripheral sensorimotor neuropathy 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Peritonitis 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Pneumonitis 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Small intestinal perforation 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Systolic dysfunction 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Vision blurred 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Vomiting 0.4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Creatinine increased 0.9%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Diarrhea 0.9%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Electrocardiogram QTc interval prolonged 0.9%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Fatigue 0.9%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Hypertension 0.9%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Pyrexia 0.9%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Asthenia 1.7%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Skin disorder 2.5%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Dermatitis bullous grade 3, 0.4%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Erysipelas grade 3, 0.4%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Palmar-plantar erythrodysaesth. grade 3, 0.4%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Pneumonitis grade 3, 0.4%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Skin candida grade 3, 0.4%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Skin exfoliation grade 3, 0.4%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Respiratory failure grade 3, 0.8%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Acneiform dermatitis grade 3, 0.9%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Headache grade 3, 1%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Nausea grade 3, 1%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Pruritus grade 3, 1%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Vomiting grade 3, 1%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Weight decreased grade 3, 1%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Generalized erythema grade 3, 1.3%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Dyspnea grade 3, 1.7%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Photosensitivity reaction grade 3, 1.7%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
ALT increased grade 3, 2%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Abdominal pain grade 3, 2%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Depression grade 3, 2%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Glucose increased grade 3, 2%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Hypocalcaemia grade 3, 2%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Photosensitivity reaction grade 3, 2%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Asthenia grade 3, 3%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Diarrhea grade 3, 3%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Rash grade 3, 3.9%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Decreased appetite grade 3, 4%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Calcium decreased grade 3, 6%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Fatigue grade 3, 6%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Hypertension grade 3, 6%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
QT interval prolonged grade 3, 8%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Calcium increased grade 3, 9%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Dermatitis acneiform grade 3, <1%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Hemoglobin decreased grade 3, <1%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Magnesium decreased grade 3, <1%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Neutrophil count decreased grade 3, <1%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Potassium decreased grade 3, <1%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Potassium increased grade 3, <1%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
WBC decreased grade 3, <1%
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
unhealthy, mean age 50.7 years
Health Status: unhealthy
Age Group: mean age 50.7 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022405Orig1s000MedR.pdf
Diarrhea grade 2, 12.5%
DLT
500 mg 1 times / day multiple, oral
Dose: 500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 500 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
unhealthy, mean age 51.6 years
Health Status: unhealthy
Age Group: mean age 51.6 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
Folliculitis grade 2, 12.5%
DLT
500 mg 1 times / day multiple, oral
Dose: 500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 500 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
unhealthy, mean age 51.6 years
Health Status: unhealthy
Age Group: mean age 51.6 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
ALT increased grade 3, 12.5%
DLT
500 mg 1 times / day multiple, oral
Dose: 500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 500 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
unhealthy, mean age 51.6 years
Health Status: unhealthy
Age Group: mean age 51.6 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
Rash grade 3, 12.5%
DLT
500 mg 1 times / day multiple, oral
Dose: 500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 500 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
unhealthy, mean age 51.6 years
Health Status: unhealthy
Age Group: mean age 51.6 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
Folliculitis grade 3, 12.5%
Disc. AE
500 mg 1 times / day multiple, oral
Dose: 500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 500 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
unhealthy, mean age 51.6 years
Health Status: unhealthy
Age Group: mean age 51.6 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
Rash grade 2, 4%
DLT
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
unhealthy, mean age 57.7 years
Health Status: unhealthy
Age Group: mean age 57.7 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
Congestive cardiac failure grade 3, 4%
Disc. AE
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
unhealthy, mean age 57.7 years
Health Status: unhealthy
Age Group: mean age 57.7 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/15905307/
https://www.ema.europa.eu/en/documents/assessment-report/caprelsa-epar-public-assessment-report_en.pdf
Lymphopenia grade 3, 33.3%
100 mg 1 times / day multiple, oral
Dose: 100 mg, 1 times / day
Route: oral
Route: multiple
Dose: 100 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
unhealthy, median age 50 years
Health Status: unhealthy
Age Group: median age 50 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
Fatigue grade 3, 16.7%
200 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
unhealthy, median age 52.5 years
Health Status: unhealthy
Age Group: median age 52.5 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
Hypertension grade 3, 33.3%
DLT
200 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
unhealthy, median age 52.5 years
Health Status: unhealthy
Age Group: median age 52.5 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
Alanine aminotransferase increased grade 3, 33.3%
DLT
400 mg 1 times / day multiple, oral
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
unhealthy, median age 53 years
Health Status: unhealthy
Age Group: median age 53 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
Hypertension grade 3, 33.3%
DLT
400 mg 1 times / day multiple, oral
Dose: 400 mg, 1 times / day
Route: oral
Route: multiple
Dose: 400 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
unhealthy, median age 53 years
Health Status: unhealthy
Age Group: median age 53 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
Toxic skin eruption grade 2, 33.3%
DLT
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
unhealthy, median age 55.5 years
Health Status: unhealthy
Age Group: median age 55.5 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
Diarrhea grade 3, 33.3%
DLT
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
unhealthy, median age 55.5 years
Health Status: unhealthy
Age Group: median age 55.5 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
Headache grade 3, 33.3%
DLT
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
unhealthy, median age 55.5 years
Health Status: unhealthy
Age Group: median age 55.5 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
Hypertension grade 3, 33.3%
DLT
300 mg 1 times / day multiple, oral
Recommended|MTD
Dose: 300 mg, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
unhealthy, median age 55.5 years
Health Status: unhealthy
Age Group: median age 55.5 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/17409986/
Dyspnea 1%
Disc. AE
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Pneumonia 1.1%
Disc. AE
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Rash 1.3%
Disc. AE
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Dry skin 10%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Dermatitis acneiform 12%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Cough 13%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Vomiting 14%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Dyspnea 15%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Hypertension 16%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Anorexia 20%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Fatigue 20%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Nausea 23%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Rash 28%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Diarrhea 50%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Pruritus 6%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Constipation 9%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Dry skin grade 3-4, 0.3%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Pruritus grade 3-4, 0.5%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Dermatitis acneiform grade 3-4, 0.6%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Cough grade 3-4, 0.8%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Nausea grade 3-4, 1%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Anorexia grade 3-4, 2%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Vomiting grade 3-4, 2%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Rash grade 3-4, 3%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Dyspnea grade 3-4, 4%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Fatigue grade 3-4, 4%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Hypertension grade 3-4, 4%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Diarrhea grade 3-4, 5%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://pubmed.ncbi.nlm.nih.gov/21282542/
Torsades de pointes 0.2%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/21282542/
QT interval prolonged 5.1%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/21282542/
Sudden death grade 5, 0.2%
300 mg/day 1 times / day multiple, oral
Recommended
Dose: 300 mg/day, 1 times / day
Route: oral
Route: multiple
Dose: 300 mg/day, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/21282542/
unhealthy, median age 61 years
Health Status: unhealthy
Age Group: median age 61 years
Sex: M+F
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/21282542/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1946

inducer
1087
inducer
440

inhibitor
2438
inhibitor
2507
inhibitor
2217

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1741

OATP1B1
1079

OATP1B3
961

CYP1A2
2153

CYP2A6
879

CYP2B6
926

CYP2C8
1057

CYP2E1
1060

CYP3A4/5
296

OCT2
779
FMO1
25

FMO3
77

UGT1A1
479

UGT1A3
470

UGT1A9
423

UGT1A4
399

UGT2B4
278

P-gp
2052

OATP1B1
503

OATP1B3
435

OCT2
434
CYP1A2
832
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
2333
 no
CYP2A6
911
 no
CYP2B6
1160
 no
CYP2C8
1117
 no
CYP2C9
2497
 no
CYP2E1
1146
 no
CYP3A4/5
357
 no
OATP1B1
1095
 no
P-gp
1932
 no
CYP2D6
2546
 weak [IC50 52 uM]
CYP1A2
2333
 weak
unlikely
Comment: less than 40% effect at 2uM in vitro
CYP2C9
2497
 weak
unlikely
Comment: less than 40% effect at 2uM in vitro
CYP3A4
2633
 weak
unlikely
Comment: less than 40% effect at 2uM in vitro
OATP1B3
970
 yes [IC50 18.3 uM]
OCT2
782
 yes [IC50 5.5 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
UGT1A1
479
 minor
UGT1A3
470
 minor
UGT1A4
399
 minor
UGT1A9
423
 minor
UGT2B4
278
 minor
OCT2
434
 no
P-gp
2052
 no
FMO1
25
 yes
FMO3
77
 yes
OATP1B1
503
 yes
OATP1B3
435
 yes
CYP3A4
1946
 yes
yes (co-administration study)
Comment: Itraconazole does not increased exposure to vandetanib; rifampicin reduced exposure to vandetanib by 48% but increased exposure to the active N-desmethyl metabolite
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
2263
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:49960
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:49960
ChemicalBook
CB01011762
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB01011762
eMolecules
10778617
https://www.emolecules.com/cgi-bin/more?vid=10778617
MolPort
MolPort-005-942-399
https://www.molport.com/shop/molecule-link/MolPort-005-942-399
Selleck Chemicals
Vandetanib
http://www.selleckchem.com/products/Vandetanib.html
ZINC
ZINC000053683345
http://zinc15.docking.org/substances/ZINC000053683345
PubMed

PubMed

TitleDatePubMed
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
2003 Apr
Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs?
2003 Apr
ZD-6474. AstraZeneca.
2003 Dec
[Current screening for molecular target therapy of cancer].
2003 Nov
Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.
2003 Nov 17
In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model.
2004
[Anti angiogenesis].
2004 Apr
Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation.
2004 Aug
Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.
2004 Dec 15
Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.
2004 Dec 15
Hormonal regulation and functional role of vascular endothelial growth factor a in the rat testis.
2004 Feb
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
2004 Jan 15
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.
2004 Nov 15
ZD6474 headed for phase III trials in the fall.
2005 Aug
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.
2005 Aug
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.
2005 Jun 15
Gateways to clinical trials.
2005 Mar
Update on angiogenesis inhibitors.
2005 Nov
Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.
2005 Nov-Dec
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
2006
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.
2006 Aug
ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib.
2006 Dec
ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy.
2006 Jan 1
Multi-target inhibitors in non-small cell lung cancer (NSCLC).
2006 Mar
Gateways to clinical trials.
2006 Sep
Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer.
2007 Feb
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.
2007 Feb
Pharmacology of epidermal growth factor inhibitors.
2007 Jan-Mar
Novel inhibitors of VEGF receptors-1 and -2 based on azole-5-carboxamide templates.
2007 Jul 1
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.
2007 Jun
1H-1,2,4-triazol-3-yl-anilines: novel potent inhibitors of vascular endothelial growth factor receptors 1 and 2.
2007 May
Combination of target agents: challenges and opportunities.
2007 May
Patents

Patents

07173038
1
08163926
1
08642608
2
20030144298
5
JP2006524634A
46
JP2011513364A
6
JP2011529067A
37
JP4701159B2
91

Sample Use Guides

In Vivo Use Guide
300 mg once daily may be taken with or without food. Dosage reduction may be necessary in the event of severe toxicities or QTc interval prolongation. The starting dose is 200 mg in patients with moderate to severe renal impairment.
Route of Administration: Oral
In Vitro Use Guide
Used in in vitro co-culture tubule formation model consisting of HUVECs and human fibroblasts vandetanib potently inhibited each of the tubule growth parameters measured (number of branch points [IC50 = 33.23 nM], total vessel length [IC50 = 60.97 nM], tubule area [IC50 = 92.70 nM]), at potencies consistent with the potency of vandetanib for inhibition of VEGF-stimulated proliferation of HUVECs.
Name Type Language
VANDETANIB
DASH   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
CAPRELSA
Preferred Name English
GNF-PF-2188
Code English
VANDETANIB [VANDF]
Common Name English
VANDETANIB [MART.]
Common Name English
NSC-744325
Code English
vandetanib [INN]
Common Name English
NSC-760766
Code English
ZD6474
Code English
N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine
Systematic Name English
VANDETANIB [USAN]
Common Name English
VANDETANIB [JAN]
Common Name English
VANDETANIB [MI]
Common Name English
VANDETANIB [ORANGE BOOK]
Common Name English
4-QUINAZOLINAMINE, N-(4-BROMO-2-FLUOROPHENYL)-6-METHOXY-7-((1-METHYL-4- PIPERIDINYL)METHOXY)-
Systematic Name English
ZD-64
Code English
ZACTIMA
Brand Name English
ZD-6474
Code English
Vandetanib [WHO-DD]
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS CAPRELSA (AUTHORIZED: THYROID NEOPLASMS)
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
LIVERTOX NBK548169
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
NDF-RT N0000175605
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
NCI_THESAURUS C1742
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
NCI_THESAURUS C2167
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
EU-Orphan Drug EU/3/05/344
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
WHO-ATC L01XE12
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
NCI_THESAURUS C93259
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
FDA ORPHAN DRUG 211005
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
WHO-VATC QL01XE12
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
Code System Code Type Description
IUPHAR
5717
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
NDF-RT
N0000185503
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY P-Glycoprotein Inhibitors [MoA]
EVMPD
SUB29174
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
ChEMBL
CHEMBL24828
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
NSC
744325
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
USAN
SS-07
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
DRUG CENTRAL
4178
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
NDF-RT
N0000187061
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY Organic Cation Transporter 2 Inhibitors [MoA]
NCI_THESAURUS
C2737
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
CAS
443913-73-3
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
HSDB
8198
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
DAILYMED
YO460OQ37K
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
WIKIPEDIA
Vandetanib
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
NSC
760766
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
INN
8365
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
EPA CompTox
DTXSID1046681
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
MERCK INDEX
m11387
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY Merck Index
LACTMED
Vandetanib
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
DRUG BANK
DB05294
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
PUBCHEM
3081361
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
SMS_ID
100000090715
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
CHEBI
49960
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
FDA UNII
YO460OQ37K
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
RXCUI
1098413
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY RxNorm
MESH
C452423
Created by admin on Mon Mar 31 18:16:51 GMT 2025 , Edited by admin on Mon Mar 31 18:16:51 GMT 2025
PRIMARY
ACTIVE MOIETY
Structure of VANDETANIB
METABOLITE ACTIVE (PARENT)
Structure of N-DESMETHYL VANDETANIB
METABOLITE INACTIVE (PARENT)
Structure of N-OXIDE VANDETANIB
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966